Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Chin, Jason ^a   Hickey, Martha ^b   Konje, Justin ^c  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION;

EID: 55049084699     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007245     Document Type: Review

References (9)

1. ACOG 2006 ACOG committee opinion No 336. Tamoxifen and uterine cancer. Obstetrics & Gynecology 2006;107(6):1475-8.
2. AIHW 1998 Australian Institute of Health and Welfare. Breast Cancer Survival in Australian Women 1982-1984. Cancer Series 1998; Vol. 9.
3. Cohen 2004 Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecologic Oncology 2004;Aug 94(2):256-66.
4. EBCTCG 2005 Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
5. Kedar 1994 Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al.Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318-21.
6. Parkin 2005 Parkin DM, Bray F, Ferlay J, Pisani P, CA Parkin D, Bray F, Ferlay J Pisani P CA. Global cancer statistics, 2002. Cancer Journal for Clinicians 2005;55(2):74-108.
7. Scommegna 1970 Scommegna A, Pandya GN, Christ M, Lee AW, Cohen MR. Intrauterine administration of progesterone by a slow releasing device. Fertility and Sterility 1970;21:201-10.
8. Van Leeuwen 1994 Van Leeuwen FE, Benraadt J, Coesbergh JW, Kiemeney LA, Gimbrere CH, Otter R. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:1318-21.
9. Xiao 1990 Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgest- relreleasing intrauterine device. Contraception 1990;41(4):353-62.